Cytokinetics, Inc. (CYTK)
80.80
-0.40
(-0.49%)
USD |
NASDAQ |
Jun 25, 16:00
80.80
0.00 (0.00%)
After-Hours: 20:00
Cytokinetics Accounts Receivable (Quarterly) : 6.827M for March 31, 2026
Accounts Receivable (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Accounts Receivable (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 6.827M |
| December 31, 2025 | 17.76M |
| September 30, 2025 | 1.808M |
| June 30, 2025 | 8.41M |
| March 31, 2025 | 2.012M |
| December 31, 2024 | 16.65M |
| September 30, 2024 | 0.244M |
| June 30, 2024 | 0.00 |
| March 31, 2024 | 0.834M |
| December 31, 2023 | 1.283M |
| September 30, 2023 | 2.499M |
| June 30, 2023 | 0.985M |
| March 31, 2023 | 1.006M |
| December 31, 2022 | 0.147M |
| September 30, 2022 | 2.294M |
| June 30, 2022 | 1.973M |
| March 31, 2022 | 6.056M |
| December 31, 2021 | 51.82M |
| September 30, 2021 | 0.644M |
| June 30, 2021 | 2.701M |
| March 31, 2021 | 4.514M |
| December 31, 2020 | 4.42M |
| September 30, 2020 | 4.965M |
| June 30, 2020 | 2.254M |
| March 31, 2020 | 2.704M |
| Date | Value |
|---|---|
| December 31, 2019 | 5.163M |
| September 30, 2019 | 6.576M |
| June 30, 2019 | 8.993M |
| March 31, 2019 | 4.165M |
| December 31, 2018 | 6.785M |
| September 30, 2018 | 9.156M |
| June 30, 2018 | 0.236M |
| March 31, 2018 | 18.59M |
| December 31, 2017 | 1.112M |
| September 30, 2017 | 10.00M |
| June 30, 2017 | 0.00 |
| March 31, 2017 | 0.91M |
| December 31, 2016 | 0.024M |
| September 30, 2016 | 67.00M |
| June 30, 2016 | 0.026M |
| March 31, 2016 | 0.00 |
| December 31, 2015 | 0.012M |
| September 30, 2015 | 0.047M |
| June 30, 2015 | 0.004M |
| March 31, 2015 | 0.97M |
| December 31, 2014 | 46.65M |
| September 30, 2014 | 1.191M |
| June 30, 2014 | 0.319M |
| March 31, 2014 | 2.116M |
| December 31, 2013 | 0.005M |
Accounts Receivable Definition
Account used to record sales made "on account", meaning that the company has made a sale but has not collected payment. When company collects cash as payment, the corresponding account receivable is decreased.
Accounts Receivable (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Accounts Receivable (Quarterly) Benchmarks
| Ionis Pharmaceuticals, Inc. | 73.68M |
| Bristol Myers Squibb Co. | 8.095B |
| Alnylam Pharmaceuticals, Inc. | 883.96M |
| BioMarin Pharmaceutical, Inc. | 903.91M |
| BridgeBio Pharma, Inc. | 205.23M |